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Abstract
The current studies evaluated the role of interleukin (IL)-17A in the induction of protective immunity against pulmonary
cryptococcosis in mice. Protection against pulmonary infection with C. neoformans strain H99c was associated with
increased IL-17A production. Signaling through the IFN-c receptor (R) was required for increased IL-17A production,
however, a Th17-type cytokine profile was not observed. Neutrophils were found to be the predominant leukocytic source
of IL-17A, rather than T cells, suggesting that the IL-17A produced was not part of a T cell-mediated Th17-type immune
response. Depletion of IL-17A in mice during pulmonary infection with C. neoformans strain H99c resulted in an initial
increase in pulmonary fungal burden, but had no effect on cryptococcal burden at later time points. Also, depletion of IL-
17A did not affect the local production of other cytokines. IL-17RA2/2 mice infected with C. neoformans strain H99c
survived the primary infection as well as a secondary challenge with wild-type cryptococci. However, dissemination of the
wild-type strain to the brain was noted in the surviving IL-17RA2/2 mice. Altogether, our results suggested that IL-17A may
be important for optimal protective immune responsiveness during pulmonary C. neoformans infection, but protective Th1-
type immune responses are sufficient for protection against cryptococcal infection.
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Introduction
Cryptococcus neoformans is an opportunistic fungal pathogen that
causes pneumonia as well as life-threatening meningoencephalitis
in individuals with T cell immune deficiencies [1–5]. Previous
studies have shown that protective immunity against this organism
is dependent upon the induction of Th1-type cytokine responses
[3,5–16]. Additional studies have also shown that increased IL-
17A production is associated with reduced cryptococcal burden
[14,16,17], suggesting that IL-17A also has a significant role in the
generation of protective anti-cryptococcal immune responses.
IL-17A is a proinflammatory cytokine produced by a subset of
CD4+ T cells, termed Th17 cells (reviewed in [18–20]). The
primary function of Th17-type T cells is clearance of pathogens
that are not adequately handled by Th1 and Th2 cells [20].
Recent reviews suggest that Th17 cells are able to bridge innate
and adaptive immune responses [19]. Th17 cells are potent
inducers of additional inflammatory mediators, such as TNF-a,
IL-1b, and IL-6 (reviewed in [18]). Although the response is
termed ‘‘Th17’’ due to the capacity of CD4+ T cells to produce IL-
17 [18,19,21,22], T cells are not the only source of IL-17. Other
sources of IL-17 include cd T cells, CD8+ T cells, NKT cells, NK
cells, and neutrophils (reviewed in [19,20,23]) [18,21,22,24–28].
The cytokines TGF-b and either IL-6 or IL-21 are required to
induce IL-17 production from naı¨ve CD4+ T cells in mice. IL-21
produced by Th17 cells amplifies the frequency of Th17 cells
[20,29], and IL-23 perpetuates the response and induces IL-17
production from memory CD4+ T cells [20]. IL-6 and TGF-b,
while inducing Th17 cells, also inhibit the generation of T
regulatory (Treg) cells [30]. Furthermore, IL-17A can elicit the
production of G-CSF and KC (CXCL1), which both can induce
neutrophil chemotaxis [21,31,32].
IL-17 has been shown in some infectious disease models, such as
Staphylococcus aureus, Bordetella bronchiseptica, and Bacteroides fragilis, to
contribute to exacerbated disease [33,34]. However, in other
models of bacterial infection, IL-17 was associated with protective
immune responses [33,35–39]. Specifically, Th17 cells have been
associated with protective immune responses in the lung against
several bacterial pathogens, including Mycoplasma pneumoniae,
Bordetella pertussis, and Mycobacterium tuberculosis (reviewed in [26]).
Similarly, IL-17 has been shown to have roles in both resistance
and susceptibility against a variety of fungal infections. Neutral-
ization of IL-23 or IL-17 during disseminated and oral candidiasis
as well as during pulmonary aspergillosis exacerbates pathology,
demonstrated by decreased neutrophil infiltration, increased
fungal burden, and reduced levels of chemokines [40–42]. IL-17
is also associated with protection against Pneumocystis carinii
infection [43]. In contrast, studies have shown that Th17 cell
activation promoted deleterious inflammation and defective fungal
clearance in pulmonary aspergillosis and gastrointestinal candidi-
asis [44]. Further, in vitro C. neoformans studies showed that IL-17
treatment reduced yeast proliferation and yeast expulsion from
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macrophages compared to IL-4 and IL-13 treated macrophages
[45]. Previous work in a mouse model of cryptococcal infection
suggested that a Th17-type response and IL-17 production are
important for modulating survival against cryptococcosis [46]. We
have established a model in which infection with an interferon-
gamma-producing C. neoformans strain, H99c, elicits protective host
immunity against pulmonary cryptococcosis in mice [14,16]. This
model system has been beneficial towards studying protective
immunity against pulmonary cryptococcosis. These studies have
shown that pulmonary infection with C. neoformans strain H99c, but
not wild-type cryptococcci, results in increased pulmonary
production of IL-17A [14]. Our observation of high levels of IL-
17A in protected mice led to our hypothesis that IL-17A
contributes to protective anti-cryptcoccal immune responses.
The purpose of these studies was to determine the role of IL-
17A in protection against Cryptococcus neoformans pulmonary
infections.
Results
Pulmonary C. neoformans strain H99c infection induces
IL-17A production but not a Th17-type cytokine profile
Previous studies in our laboratory have shown that infection
with an IFN-c-producing C. neoformans strain, H99c, results in a
significant increase in pulmonary IL-17A cytokine production on
day 7 post-inoculation compared to mice infected with the
parental C. neoformans strain H99 [14,16]. However, it remains
unclear whether the increase in IL-17A production observed in the
lungs of mice infected with C. neoformans strain H99c is coupled to
an overall Th17-type cytokine response. We therefore determined
the expression of cytokines associated with the induction of Th17-
cytokine responses (IL-6, IL-17A, IL-21, IL-23, and TGF-b) in
total lung homogenates derived from mice infected with wild-type
C. neoformans strain H99 or the transgenic C. neoformans strain H99c
on day 7 post-inoculation. We observed a significant increase in
IL-6 and IL-17 (Figure 1) in lung homogenates derived from C.
neoformans strain H99c infected mice compared to those obtained
from mice infected with wild-type yeast (P,0.0001 for IL-6 and
IL-17A) as previously described [14]. However, no significant
differences in the production of IL-21, IL-23, or TGF-b were
observed in the lungs of mice infected with wild-type C. neoformans
strain H99 compared to mice infected with the transgenic C.
neoformans strain H99c. Thus, the significant increase in IL-17A
production observed in the lungs of mice during infection with the
transgenic C. neoformans strain H99c appears not to be associated
with a general induction of Th17-type cytokines.
Neutrophils are the predominant source of IL-17A in
mice infected with C. neoformans strain H99c
We sought to determine the leukocyte population that was the
predominant source of IL-17A in the lungs of mice infected with C.
neoformans strain H99c. Total leukocytes were isolated from lung
tissues of naı¨ve mice and C. neoformans strain H99c-infected mice
on day 7 post-challenge, and the lymphocyte subpopulations
characterized for intracellular IL-17A expression by flow cytom-
etry. Leukocyte populations examined included CD4+ T cells,
CD8+ T cells, cd T cells, regulatory T cells, natural killer T cells,
macrophages, dendritic cells, neutrophils, B cells, eosinophils, and
mast cells. Figure 2 demonstrates that the majority of intracellular
IL-17A expression in both naı¨ve mice and mice infected with C.
neoformans strain H99c was observed in Ly6G+ neutrophils
(detected with the 1A8 monoclonal antibody). We also observed
that mice infected with C. neoformans strain H99c had significantly
higher intracellular IL-17A in total CD45+ cells, CD4+ T cells, and
dendritic cells compared to naı¨ve mice. Although neutrophils
appear to be the predominant source of IL-17A, we cannot
conclude that increased IL-17A production by other cell types in
response to C. neoformans strain H99c infection does not contribute
to the observed phenotype. Representative flow cytometry plots
are shown in Figure S1.
Increased pulmonary IL-17A production in C. neoformans
strain H99c infected mice involves IFN-c receptor (R)
signaling
Our studies suggest that signaling through the IFN-cR may be
necessary for the increase in IL-17A production observed in the
lungs of mice inoculated with C. neoformans strain H99c. To
evaluate this hypothesis, IFN-cR2/2 and wild-type (WT) BALB/c
mice were inoculated with C. neoformans strain H99c or C.
neoformans strain H99 and thereafter examined for pulmonary
fungal burden, cytokine production, and leukocyte infiltration at
Figure 1. Pulmonary infection with C. neoformans strain H99c results in significant IL-17A, but not Th17, cytokine production in the
lungs. BALB/c mice were given an intranasal inoculation with C. neoformans strain H99 or H99c. Lung homogenates were prepared from lungs
excised on day 7 post-inoculation and assayed for IL-6, IL-17A, IL-21, IL-23, and TGF-b cytokine production. Data are cumulative of four experiments
utilizing 5 mice each per group. Asterisks (*) indicate where significant differences were observed (P,0.0001).
doi:10.1371/journal.pone.0017204.g001
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day 7 post-infection. Results showed that IFN-cR2/2 mice had
significantly increased pulmonary fungal burden compared to WT
mice when infected with C. neoformans strain H99c, but no change
in fungal burden was detected between IFN-cR2/2 mice and WT
mice during infection with the wild-type strain, C. neoformans strain
H99 (Figure 3A). Furthermore, cytokine analysis showed that the
IFN-cR2/2 mice had significantly reduced levels of pro-
inflammatory (IL-1a, IL-1b, and IL-6), IL-12p40, IL-17, and
chemokine (G-CSF and CXCL1) production compared to WT
mice during infection with C. neoformans strain H99c (Figure 3B).
No differences were observed in cytokine production in KO vs
WT mice infected with C. neoformans strain H99.
Clearance of pulmonary cryptococcosis in IL-17A
deficient mice
Previous studies have suggested that IL-17A may play a role in
protection against experimental pulmonary crytococcosis [14]. We
therefore examined the effects of IL-17A depletion on the
development of protection in mice given an experimental
pulmonary infection with C. neoformans strain H99c. Mice were
treated intranasally with anti-IL-17A monoclonal antibody or
isotype-control antibody beginning at 4 hours post-inoculation and
continued every 4 days throughout the experiment. We observed a
significant reduction in IL-17A production in lung homogenates of
mice treated with the anti-IL-17A antibody at days 7 and 14 post-
infection compared to mice treated with the isotype control
antibody (Figure 4A). Examination of other cytokines and
chemokines in lung homogenates revealed no significant differences
between isotype-control and anti-IL-17A antibody treated mice
(Table 1). Mice treated with anti-IL-17A antibody had significantly
increased pulmonary fungal burden compared to mice treated with
the isotype control antibody (P,0.002) at day 7 post-infection
(Figure 4B). No differences in pulmonary fungal burden were
observed at day 14 post-infection (Figure 4B). Although all
leukocytes are significantly increased in infected mice compared
to naı¨ve controls, we observed no significant differences in leukocyte
populations in H99c-infected isotype control treated mice com-
pared to IL-17A depleted mice at each time point tested (Figure 5).
Although antibody depletion significantly reduced the amount
of IL-17A in lung homogenates, the depletion was not absolute.
Therefore, we evaluated survival of IL-17 receptor A knock-out
(IL-17RA2/2) mice given a pulmonary infection with C. neoformans
strain H99c. IL-17RA2/2 mice still have the ability to produce
IL-17A, but signaling through its receptor, IL-17RA, is abrogated
[47]. Figure 6A demonstrates 100% survival of WT and IL-
17RA2/2 mice given a primary pulmonary infection with C.
neoformans strain H99c through day 35 post-inoculation. All
surviving WT and IL-17RA2/2mice were subsequently re-
challenged with the non-IFN-c producing wild-type C. neoformans
strain H99 on day 35 post-primary inoculation and also
demonstrated 100% survival through day 28 post-secondary
challenge (Figure 5B). Culture of tissue homogenates derived from
re-challenged WT and IL-17RA2/2 mice at day 28 post-
secondary inoculation indicated no significant difference in fungal
burden in lung or brain tissues (Figure 6C). Evidence of
dissemination to the spleen was not observed in any surviving
wild-type mice, but was observed in one surviving knock-out
mouse. Interestingly, following differential plating on YPD media
with and without nourseothricin (a selectable marker for the H99c
strain), colonization of spleen and brain was due to the challenge
organism, strain H99, while the colonization of the lungs was due
to the immunizing organism, strain H99c. Our results suggest that
IL-17A contributes to, but is not required for, the resolution of
acute infection with C. neoformans strain H99c. However, IL-17RA
signaling may be needed to prevent dissemination of cryptococci
from the lung to the CNS of immunized mice following re-
challenge with WT cryptococci.
Discussion
IL-17A and the Th17 response have been shown to be
important in protection against multiple infectious pathogens.
Previous studies suggesting that IL-17A is associated with
protective immune responses against C. neoformans [16] led us to
investigate its contribution in our model of complete protection
against experimental pulmonary cryptococcosis. Contrary to
reports suggesting that IFN-c suppresses IL-17A production
[39,48], we found that in the absence of IFN-cR signaling, IL-
17A production is significantly reduced during pulmonary
infection with C. neoformans strain H99c. Previous results in our
Figure 2. Lung neutrophils are the predominant leukocyte population expressing IL-17A during pulmonary infection with C.
neoformans strain H99c. BALB/c mice received an intranasal inoculum of 16104 CFU of C. neoformans strain H99c in 50 ml of sterile PBS (gray bars).
Naı¨ve Balb/c mice (white bars) are shown as controls. The lungs were excised at day 7 post-inoculation and a single cell suspension generated using
enzymatic digestion. The leukocytes were stained with anti-mouse antibodies (CD45, 1A8 (Neut) CD4, CD8, F4/80 (Mac), CD11b/CD11c (DC), CD4/
Fox3p (Treg), CD4/DX5 (NKT),cd, B220 (B cell), SiglecF/CD11b (Eosinophil), FceR1a/CD117/CD34 (Mast cell)), fixed, permeabilized, and incubated with
anti-mouse antibodies specific for IL-17A and quantified by flow cytometry. Flow cytometry data are cumulative results of five independent
experiments using pooled leukocytes from 5 mice per group per experiment. Results shown are the percentage of leukocytes expressing the
indicated surface markers and IL-17A. Asterisks (*) indicate where significant differences were observed (P,0.0001) between naı¨ve mice and mice
infected with C. neoformans strain H99c.
doi:10.1371/journal.pone.0017204.g002
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laboratory have shown that IL-17A production in IFN-c KO mice
is similar to that observed in WT mice following infection with C.
neoformans strain H99c [49]. Therefore, signaling through the IFN-
c receptor may directly or indirectly influence IL-17A production
in our model system, but is not entirely responsible for IL-17A
production. Further, the presence or absence of the IFN-c
cytokine does not affect IL-17A production [49]. These results
suggest that in our model, IL-17A works in collaboration with the
protective Th1-type immune response as reported in studies of
protection against other infectious pathogens [18,45].
Elevated IL-17A production in the lungs correlates with
protective immune responses against cryptococcal infection and
resolution of infection [14,16]. Indeed, our results herein suggest
that IL-17A may be involved in the protective response at early
time points, since increased fungal burden is evident in mice
treated with anti-IL-17A at day 7 post-inoculation with C.
neoformans strain H99c. One important function of IL-17A, that
of a neutrophil chemoattractant [21,31], was not observed in our
studies (Figure 5). Also, depletion of IL-17A during infection with
C. neoformans strain H99c resulted in no changes in any other
pulmonary cytokine tested. Despite early differences in pulmonary
fungal burden, mice depleted of IL-17A and IL-17RA2/2 mice
eventually resolve the pulmonary infection, suggesting that
alternative protective mechanisms may be present in mice lacking
IL-17A or in mice lacking signalling through the IL-17 receptor.
Interestingly, the surviving IL-17R2/2 animals all had detectable
brain colonization with C. neoformans strain H99, suggesting that
these animals had difficulty preventing dissemination of the wild-
type cryptococci, even though they showed no signs or symptoms
of disease.
Our studies examining IL-17A expression within lung leuko-
cytes during C. neoformans strain H99c infection suggest that
neutrophils are the predominant source of IL-17A, rather than
CD4+ T cells, which has been shown in other systems [22,50,51].
Results from other fungal infection model systems also suggested
that multiple cell types can produce IL-17A (reviewed in [28]).
Our data suggest that the IL-17A produced during protective anti-
C. neoformans immune responses is not associated with an overall
Th17-type cytokine response. Th17 responses are associated with
the production of IL-21, IL-23, and TGF-b; none of which are
significantly increased in the lungs of protected mice in our model
(Figure 1). IL-17RA deficiency as well as treatment with anti-IL-
17A neutralizing antibodies has been shown to decrease neutrophil
infiltration and production of G-CSF [23]. Further, IL-17A
regulates neutrophils by inducing G-CSF production and controls
expansion of IL-17A-producing neturophil regulating T cells
through the IL-17RA [23]. In contrast, we did not observe any
change in neutrophil recruitment in mice treated with anti-IL-17A
antibodies (Figure 5), further suggesting that IL-17A alone was not
required to induce neutrophil recruitment to the lungs in response
to C. neoformans H99c infection.
Since complete protection is only observed during acute
infection in mice infected with C. neoformans strain H99c and not
in mice infected with wild-type cryptococci, this model has been
beneficial in evaluating the impact of various components of host
immunity on the resolution of experimental pulmonary crypto-
coccosis. In our model, infection of mice with an IFN-c-producing
C. neoformans strain, H99c, leads to increased production of IL-
17A, resolution of the acute infection, and protection against
challenge with wild-type C. neoformans [14,16,52]. Our studies show
that the significant increase in IL-17A production requires IFN-c
receptor signaling and is likely not associated with a Th17-type
immune response. Furthermore, neutrophils appeared to be the
predominant leukocyte population expressing IL-17A. Taken
together, our studies show that although IL-17A may contribute
to immune defenses against pulmonary infection with C. neoformans
Figure 4. IL-17A depletion does not affect resolution of cryptococcal infection. BALB/c mice were infected with C. neoformans strain H99c,
and then treated with 100 mg of anti-IL-17A neutralizing antibody or isotype control IgG2a via the intranasal route four hours following infection.
Treatment was repeated every four days thereafter. The lungs from depleted mice and isotype control-treated mice were excised at days 7 and 14
post inoculation and assayed for IL-17A production (A) and cryptococcal fungal burden (B). Data are cumulative of five experiments utilizing 5 mice
per group. Asterisks (*) indicate where significant decreases were observed in IL-17A depleted mice compared to isotype-control treated mice
following infection with C. neoformans strain H99c (P,0.05). Separate mice were used for each time point.
doi:10.1371/journal.pone.0017204.g004
Figure 3. Induction of IL-17A production during C. neoformans strain H99c infection requires IFN-cR expression. BALB/c and IFN-cR2/2
mice were given an intranasal inoculation with either C. neoformans strain H99 or H99c. Naı¨ve mice were used as controls for pulmonary cytokines.
Lungs were excised at day 7 post-inoculation, and pulmonary cryptococcal burden (A) and cytokine production (B) quantified. Fungal burden results
are expressed as mean log CFU per milliliter 6 standard errors of the means. A. Asterisks (*) indicate where significant decreases in CFU were
observed in IFN-cR 2/2 mice compared to wild-type BALB/c mice (P,0.01). B. Asterisks (*) indicate where significant differences in cytokines were
observed (P,0.02). Data are cumulative of two experiments using 5 mice per group.
doi:10.1371/journal.pone.0017204.g003
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strain H99c, alternative mechanisms, namely Th1-type host
responses, are predominantly responsible for the resolution of
pulmonary C. neoformans infection.
Materials and Methods
Ethics
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. Mice were housed at
The University of Texas at San Antonio Small Animal Laboratory
Vivarium. These animal experiments were approved by The
University of Texas at San Antonio Institutional Animal Care and
Use Committee (IACUC), approved protocol number MU021-11/
11A2, and mice were handled according to IACUC guidelines. All
efforts were made to minimize animal suffering.
Mice
Female BALB/c (H-2d) (National Cancer Institute/Charles
River Laboratories, Boston, MA and The Jackson Laboratory, Bar
Harbor, ME), IFN-cR2/2 (The Jackson Laboratory), and IL-17
receptor A knock out (IL-17RA2/2) mice (a kind gift of Jay K.
Kolls, Louisiana State University Health Sciences Center, New
Orleans, LA), all on the BALB/c background with an average
weight of 20–25 grams, were used throughout these studies.
Strains and media
C. neoformans strains H99 (serotype A, Mat a) and H99c
(serotype A, Mat a, an interferon-gamma producing strain derived
from C. neoformans H99 [14]) were recovered from 15% glycerol
stocks stored at –80uC prior to use in the experiments described
herein. The strains were maintained on yeast-extract-peptone-
dextrose (YPD) media (1% yeast extract, 2% peptone, 2%
dextrose, and 2% Bacto agar). Yeast cells were grown for 18–
20 h at 30uC with shaking in YPD broth (Becton Dickinson and
Company, Sparks, MD), collected by centrifugation, washed three
times with sterile phosphate-buffered saline (PBS), and viable yeast
quantified using trypan blue dye exclusion in a hemacytometer.
Pulmonary infections
Pulmonary C. neoformans infections were initiated by nasal
inhalation as previously described [16,53,54]. BALB/c mice were
anesthetized with 2% isoflurane using a rodent anesthesia device
(Eagle Eye Anesthesia, Jacksonville, FL) and then given a yeast
inoculum of 16104 colony forming units (CFU) of C. neoformans strains
H99 or H99c in 50 ml of sterile PBS pipetted directly into the nares.
The inocula used were verified by quantitative culture on YPD agar.
The mice were fed ad libitum and were monitored by inspection
twice daily. Mice were euthanized at specific time points post-
inoculation by CO2 inhalation followed by cervical dislocation, and
lung tissues were excised using aseptic technique. Tissues were
homogenized in 1 ml of sterile PBS, followed by culture of 10-fold
dilutions of each tissue on YPD agar supplemented with chloram-
phenicol (Mediatech, Inc., Herndon, VA). CFU were enumerated
following incubation at 30uC for 48 h. Alternatively, mice intended
for survival analysis were monitored by inspection twice daily and
euthanized if they appeared to be in pain or moribund.
Pulmonary leukocyte isolation
Lungs were excised at specific time points post- inoculation and
digested enzymatically at 37uC for 30 minutes in 10 ml of
digestion buffer (RPMI 1640 and 1 mg/ml of collagenase type IV
[Sigma-Aldrich, St. Louis, MO.]) with intermittent (every 10 min)
stomacher homogenizations. The enzymatically-digested tissues
were then successively filtered through sterile nylon filters of
various pore sizes (70 and 40 mm) (BD Biosciences) and washed
with sterile HBSS to enrich for leukocytes. Erythrocytes were lysed
by incubation in NH4Cl buffer (0.859% NH4Cl, 0.1% KHCO3,
0.0372% Na2EDTA [pH 7.4]; Sigma-Aldrich) for 3 minutes on
ice followed by the addition of a 10-fold excess of PBS. The
resulting leukocyte population was then collected by centrifugation
(8006g) for 5 minutes, washed twice with sterile PBS, resuspended
in sterile PBS+ 2% heat-inactivated fetal bovine serum (FACS
buffer) and enumerated in a hemacytometer using trypan blue dye
exclusion. Flow cytometric analysis was used to determine the
percentage of each leukocyte population as well as the absolute
number of total leukocytes (CD45+) within the lung cell suspension
for standardization of hemacytometer counts.
Cytokine depletions
For anti-IL-17A experiments, mice received 100 mg anti-IL-17A
in a volume of 25 ml pipetted directly into the nares, beginning
4 hours post-inoculation and continuing every 4 days throughout
the study. Controls for these experiments included mice treated
with isotype control antibody via the intranasal route.
Antibodies
For flow cytometry experiments, cells were incubated with
CD16/CD32 (Fc BlockTM) (BD Biosciences, San Diego, CA) and
Table 1. Pulmonary cytokine production in IL-17A depleted
mice during infection with C. neoformans strain H99c.
Isotype D7 Anti-IL-17 D7 Isotype D14
Anti-IL-17
D14
Th1
IL-2 29.263.7 25.563.2 16.361.2 13.361.1
IL-12p40 118.6611.3 113.3612.2 106.5622.5 111.5611.1
IL-12p70 29.665.2 35.865.6 17.565.8 17.064.5
IFN-c 22.963.5 22.164.3 21.363.3 19.063.8
Th2
IL-4 61.768.4 55.1610.7 12.564.8 8.768.7
IL-5 7.361.1 9.962.5 2.760.6 2.260.4
IL-10 7.860.9 7.761.2 4.160.8 2.960.6
Th17
IL-17 182.96 30.0 28.264.0* 31.866.2 17.263.4*
IL-6 54.266.7 58.265.5 2.160.6 1.260.3
Pro-
inflammatory
IL-1a 63.26 6.04 79.967.2 35.56 9.6 27.063.0
IL-1b 775.36102.9 757.0698.2 455.66129.1 396.3681.5
TNF-a 10.261.4 9.961.4 9.862.1 9.462.1
G-CSF 375.5676.7 313.0641.6 16.064.6 10.5661.7
Chemokines
MCP-1 1043.0690.3 1069.06114.9 203.1626.4 169.869.1
MIP1a 527.4685.7 562.9695.8 298.1641.5 303.1635.9
MIP1b 69.1611.8 65.6612.0 15.262.7 11.861.3
RANTES 263.4631.8 280.1642.0 278.6636.7 303.3622.9
KC 584.9697.6 520.5692.2 310.06111.3 175.1650.9
* = significant reduction (P,0.05) compared to isotype control-treated mice at
the same time point.
doi:10.1371/journal.pone.0017204.t001
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Figure 5. IL-17A depletion does not affect pulmonary leukocyte recruitment. BALB/c mice were infected with C. neoformans strain H99c,
and then treated with 100 mg of anti-IL-17A neutralizing antibody or isotype control IgG2a via the intranasal route four hours following infection.
Treatment was repeated every four days thereafter. Naı¨ve mice were used as controls for pulmonary leukocyte populations. The lungs from depleted
mice and isotype control-treated mice were excised at days 7 and 14 post inoculation and assayed for leukocyte populations by flow cytometry. Data
are cumulative of five experiments utilizing 5 mice per group. Separate mice were used for each time point.
doi:10.1371/journal.pone.0017204.g005
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the following antibodies conjugated to phycoerythrin (PE),
allophycocyanin (APC), Alexa 647, or PECy7 were added: a
cocktail of CD3, CD4, and CD8a; CD45, MHC class II, B220,
Siglec-F (BD Biosciences), 1A8, CD11c, CD11b, F4/80, DX5,
Fox3P, cd, MHC class II, CD86, IL-17A, FceR1a CD117, CD34
(eBioscience Inc.), and F4/80 (Caltag Laoratories, Burlingame,
CA).
Flow cytometry
Standard methodology was employed for the direct immuno-
fluorescence of pulmonary leukocytes. Briefly, in 96-well U-bottom
plates, 100 ml containing 16106 cells in PBS + 2% FBS (FACS
buffer) were incubated with 50 ml of Fc BlockTM (BD Biosciences)
diluted in FACS buffer for 5 minutes to block non-specific binding
of antibodies to cellular Fc receptors. Subsequently, an optimal
concentration of fluorochrome-conjugated antibodies (between
0.06–0.5 mg/16106 cells in 50 ml of FACS buffer) were added in
various combinations to allow for dual or triple staining
experiments, and plates were incubated for 30 minutes at 4uC.
Following incubation, the cells were washed three times with
FACS buffer and cells were fixed in 200 ml of 2% ultrapure
formaldehyde (Polysciences, Inc., Warrington, PA) diluted in
FACS buffer (fixation buffer). For intracellular staining, cells
remained in fixation buffer for 10 min at room temperature. After
fixation, the cells were washed and permeabilized with 0.1%
saponin for 10 min at room temperature. While permeabilized,
the cells were intracellularly stained with anti-IL-17A (eBioscience
Inc.) and/or anti-Fox3P (regulatory T cell) (eBioscience Inc.) for
30 min at 4uC. Cells were then washed 3 times with 0.1% saponin
and then resuspended in fixation buffer before flow cytometry was
performed. Cells incubated with either FACS buffer alone or
single fluorochrome-conjugated antibodies were used to determine
positive staining and spillover/compensation calculations, and the
flow cytometer determined background fluorescence. The samples
were analyzed using BD FACSArray softwareTM on a BD
FACSArray flow cytometer (BD Biosciences). Dead cells were
excluded on the basis of forward angle and 90u light scatter. For
data analyses, 30,000 events (cells) were evaluated from a
predominantly leukocytic population identified by backgating
from CD45+-stained cells. The absolute number of total leukocytes
was quantified by multiplying the total number of cells observed by
hemacytometer counting by the percentage of CD45+ cells
determined by flow cytometry. The absolute number of each
leukocyte subset (1A8, F4/80+, CD11c+/CD11b+, CD11c+/
CD11b+/MHC class II+, CD11c+/CD11b+/CD86+, B220+,
MHC class II+, CD4+/CD3+ CD8+/CD3+, CD4+/Fox3p+,
CD4+/DX5+, Siglec-F+/CD11b+, FceR1a+/CD117+/CD34+
was determined by multiplying the percentage of each gated
population by the total number of CD45+ cells.
Cytokine analysis
Cytokine levels in lung tissues were analyzed using the Bio-Plex
Protein Array System (Luminex-based technology) (Bio-Rad
Laboratories, Hercules, CA). Briefly, lung tissue was excised and
homogenized in ice-cold sterile PBS (1 ml). An aliquot (50 ml) was
taken to quantify the pulmonary fungal burden and an anti-
protease buffer solution (1 ml) containing PBS, protease inhibitors
(inhibiting cysteine, serine, and other metalloproteinases) and
0.05% Triton X-100 was added to the homogenate. Samples were
then clarified by centrifugation (8006g) for 5 minutes. Superna-
tants from pulmonary homogenates were assayed using the Bio-
Plex Protein Array System (Bio-Rad Laboratories) for the presence
of interferon (IFN)- c, interleukin (IL)-1a, IL-1b, IL-2, IL-4, IL-5,
IL-10, IL-12 p70, IL-17, tumor necrosis factor (TNF)- a, and
granulocyte-colony stimulating factor [G-CSF] expression as well
as chemokines (macrophage inflammatory protein [MIP]-1a
(CCL3), MIP-1b (CCL4), macrophage chemoattractant protein
[MCP]-1 (CCL2), keratinocyte-derived chemokine (KC)
(CXCL1), and regulated upon activation, normal T cell expressed
and secreted [RANTES] (CCL5)). ELISA assays were performed
to measure TGF-b, IL-23 (R&D Systems), and IL-21 (BD
Biosciences) on pulmonary homogenates.
Statistical analysis
The unpaired Student’s t test (two-tailed) was used to analyze
fungal burden, pulmonary cell populations, and cytokine/
chemokine data using GraphPad Prism version 5.00 for Windows
(GraphPad Prism Software, San Diego California USA). Survival
data was analyzed using the log-rank test (GraphPad Prism
Software). Significant differences were defined as P,0.05.
Supporting Information
Figure S1 Lung neutrophils are the predominant leu-
kocyte population expression IL-17A during pulmonary
infection with C. neoformans strain H99c. BALB/c mice
received an intranasal inoculum of 16104 CFU of C. neoformans
strain H99c in 50 ml of sterile PBS. Naı¨ve Balb/c mice are shown
as controls. The lungs were excised at day 7 post-inoculation and a
single cell suspension generated using enzymatic digestion. The
Figure 6. Lack of IL-17R signaling does not significantly affect resolution of infection or survival to cryptococcal infection. BALB/c
mice or IL-17RA2/2 mice received an intranasal inoculum of C. neoformans strain H99c. Mice were assayed for survival through 35 days of primary
infection with C. neoformans strain H99c (A). Surviving mice were then challenged with C. neoformans strain H99 and assayed for survival through 28
days of secondary challenge (B). Culture of lung, spleen, and brain tissues at day 28 post-secondary challenge were determined from mice with
positive cultures (C) and numbers of mice with positive cultures are shown above each bar. Survival data show one experiment containing nine WT
and eight IL-17RA2/2 mice. Asterisks (*) indicate where significant differences in fungal burden were observed in IL-17RA2/2 mice compared to WT
mice following infection with C. neoformans strain H99 (P,0.0001).
doi:10.1371/journal.pone.0017204.g006
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leukocytes were stained with anti-mouse antibodies (CD45, 1A8
(Neut) CD4, CD8, F4/80 (Mac), CD11b/CD11c (DC), CD4/
Fox3p (Treg), CD4/DX5 (NKT),cd, B220 (B cell), SiglecF/
CD11b (Eosinophil), FceR1a/CD117/CD34 (Mast cell)), fixed,
permeabilized, and incubated with anti-mouse antibodies specific
for IL-17A and quantified by flow cytometry. Flow cytometry dot
plots are representative data of five independent experiments using
pooled leukocytes from 5 mice per group per experiment. Results
shown in the upper right quadrant of each plot are the percentage
of leukocytes expressing the indicated surface markers and IL-17A.
(TIF)
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